Endothelial dysfunction: The common consequence in diabetes and hypertension

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 4, 2010, Pages 300-307

  Wong, Wing Tak ^a   Wong, Siu Ling ^a   Tian, Xiao Yu ^a   Huang, Yu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Diabetes; Endothelial dysfunction; Hypertension

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ARACHIDONIC ACID; ASCORBIC ACID; CELECOXIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIUM DERIVED RELAXING FACTOR; INDOMETACIN; LOSARTAN; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THROMBOXANE A2; TROGLITAZONE;

BLOOD VESSEL TONE; CONFERENCE PAPER; DIABETES MELLITUS; DRUG ACTIVITY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; GLYCATION; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR SMOOTH MUSCLE; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES COMPLICATIONS; METABOLISM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION;

EID: 77951737282     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181d7671c     Document Type: Article

References (137)

1. Morgan CL, Currie CJ, Stott NC, et al. The prevalence of multiple diabetes-related complications. Diabet Med. 2000;17:146-151.
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
3. Marks JB, Raskin P. Cardiovascular risk in diabetes: a brief review. J Diabetes Complications. 2000;14:108-115.
4. Grossman E, Messerli FH, Goldbourt U. High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med. 2000;160:2447-2452.
5. Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med. 2001;111:633-642.
6. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endotheliumdependent and independent vasodilation in patients with type 2 (noninsulin- dependent) diabetes mellitus. Diabetologia. 1992;35:771-776.
7. Johnstone MT, Creager SJ, Scales KM, et al. Impaired endotheliumdependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993;88:2510-2516.
8. Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxidemediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27:567-574.
9. Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999;48:1856-1862.
10. Panza JA, Casino PR, Kilcoyne CM, et al. Impaired endotheliumdependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol. 1994;23:1610-1616.
11. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation. 1993;87:86-93.
12. Park JB, Charbonneau F, Schiffrin EL. Correlation of endothelial function in large and small arteries in human essential hypertension. J Hypertens. 2001;19:415-420.
13. Scherrer U, Sartori C. Defective nitric oxide synthesis: a link between metabolic insulin resistance, sympathetic overactivity and cardiovascular morbidity. Eur J Endocrinol. 2000;142:315-323.
14. Fang TC, Wu CC, Huang WC. Inhibition of nitric oxide synthesis accentuates blood pressure elevation in hyperinsulinemic rats. J Hypertens. 2001;19:1255-1262.
15. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286: 327-334.
16. Luscher TF. Imbalance of endothelium-derived relaxing and contracting factors. A new concept in hypertension? Am J Hypertens. 1990;3:317-330.
17. Vanhoutte PM, Shimokawa H, Tang EH, et al. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf). 2009;196:193-222.
18. Vanhoutte PM. COX-1 and vascular disease. Clin Pharmacol Ther. 2009;86:212-215.
19. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994;46:205-229.
20. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (TheWiggers Award Lecture). Am J Physiol Heart Circ Physiol. 2006;291:H985-H1002.
21. Thomas SR, Witting PK, Drummond GR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal. 2008;10:1713-1765.
22. Miller VM, Vanhoutte PM. Enhanced release of endothelium-derived factor(s) by chronic increases in blood flow. Am J Physiol. 1988;255: H446-H451.
23. Busse R, Fleming I. Regulation of endothelium-derived vasoactive autacoid production by hemodynamic forces. Trends Pharmacol Sci. 2003;24:24-29.
24. Leung FP, Yung LM, Laher I, et al. Exercise, vascular wall and cardiovascular diseases: an update (Part 1). Sports Med. 2008;38:1009-1024.
25. Yung LM, Laher I, Yao X, et al. Exercise, vascular wall and cardiovascular diseases: an update (part 2). Sports Med. 2009;39:45-63.
26. Colacurci N, Manzella D, Fornaro F, et al. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab. 2003;88:2135-2140.
27. Leung FP, Tsang SY, Wong CM, et al. Raloxifene, tamoxifen and vascular tone. Clin Exp Pharmacol Physiol. 2007;34:809-813.
28. Zhang L, Kosaka H. Sex-specific acute effect of estrogen on endothelium-derived contracting factor in the renal artery of hypertensive Dahl rats. J Hypertens. 2002;20:237-246.
29. Sarr M, Chataigneau M, Martins S, et al. Red wine polyphenols prevent angiotensin II-induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase. Cardiovasc Res. 2006;71:794-802.
30. O'Keefe JH, Gheewala NM, O'Keefe JO. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol. 2008;51:249-255.
31. Baron-Menguy C, Bocquet A, Guihot AL, et al. Effects of red wine polyphenols on postischemic neovascularization model in rats: low doses are proangiogenic, high doses anti-angiogenic. FASEB J. 2007;21: 3511-3521.
32. Tinahones FJ, Rubio MA, Garrido-Sanchez L, et al. Green tea reduces LDL oxidability and improves vascular function. J Am Coll Nutr. 2008; 27:209-213.
33. Mori TA, Watts GF, Burke V, et al. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation. 2000; 102:1264-1269.
34. Chen H, Li D, Chen J, et al. EPA and DHA attenuate ox-LDL-induced expression of adhesion molecules in human coronary artery endothelial cells via protein kinase B pathway. J Mol Cell Cardiol. 2003;35: 769-775.
35. Fleischhauer FJ, Yan WD, Fischell TA. Fish oil improves endotheliumdependent coronary vasodilation in heart transplant recipients. J Am Coll Cardiol. 1993;21:982-989.
36. Zou MH, Shi C, Cohen RA. High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes. 2002;51:198-203.
37. Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A. 1990;87: 9383-9387.
38. Yang D, Gluais P, Zhang JN, et al. Nitric oxide and inactivation of the endothelium-dependent contracting factor released by acetylcholine in spontaneously hypertensive rat. J Cardiovasc Pharmacol. 2004;43:815-820.
39. Csiszar A, Ungvari Z, Edwards JG, et al. Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res. 2002;90:1159-1166.
40. Kim JH, Bugaj LJ, Oh YJ, et al. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J Appl Physiol. 2009;107:1249-1257.
41. Kung CF, Luscher TF. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension. 1995;25:194-200.
42. Taddei S. [Aging and endothelial function]. Cardiologia. 1997;42: 1229-1236.
43. Shi Y, Man RY, Vanhoutte PM. Two isoforms of cyclooxygenase contribute to augmented endothelium-dependent contractions in femoral arteries of 1-year-old rats. Acta Pharmacol Sin. 2008;29:185-192.
44. Tang EH, Vanhoutte PM. Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension. Physiol Genomics. 2008;32:409-418.
45. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008;371: 1800-1809.
46. Tan KC, Chow WS, Ai VH, et al. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Diabetes Metab Res Rev. 2002;18:71-76.
47. Chang KC, Chung SY, Chong WS, et al. Possible superoxide radicalinduced alteration of vascular reactivity in aortas from streptozotocintreated rats. J Pharmacol Exp Ther. 1993;266:992-1000.
48. Dai FX, Diederich A, Skopec J, et al. Diabetes-induced endothelial dysfunction in streptozotocin-treated rats: role of prostaglandin endoperoxides and free radicals. J Am Soc Nephrol. 1993;4:1327-1336.
49. Elmi S, Sallam NA, Rahman MM, et al. Sulfaphenazole treatment restores endothelium-dependent vasodilation in diabetic mice. Vascul Pharmacol. 2008;48:1-8.
50. Gao X, Belmadani S, Picchi A, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice. Circulation. 2007; 115:245-254.
51. Pannirselvam M, Verma S, Anderson TJ, et al. Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db2/2) mice: role of decreased tetrahydrobiopterin bioavailability. Br J Pharmacol. 2002;136:255-263.
52. Laight DW, Carrier MJ, Anggard EE. Antioxidants, diabetes and endothelial dysfunction. Cardiovasc Res. 2000;47:457-464.
53. Vlassara H, Fuh H, Makita Z, et al. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A. 1992;89:12043-12047.
54. Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001;88:E14-E22.
55. Mezzetti A, Cipollone F, Cuccurullo F. Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. Cardiovasc Res. 2000;47:475-488.
56. Haidara MA, Yassin HZ, Rateb M, et al. Role of oxidative stress in development of cardiovascular complications in diabetes mellitus. Curr Vasc Pharmacol. 2006;4:215-227.
57. Moien-Afshari F, Ghosh S, Elmi S, et al. Exercise restores endothelial function independently of weight loss or hyperglycaemic status in db/db mice. Diabetologia. 2008;51:1327-1337.
58. Keegan A, Walbank H, Cotter MA, et al. Chronic vitamin E treatment prevents defective endothelium-dependent relaxation in diabetic rat aorta. Diabetologia. 1995;38:1475-1478.
59. Ting HH, Timimi FK, Boles KS, et al. Vitamin C improves endotheliumdependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1996;97:22-28.
60. Gazis A, White DJ, Page SR, et al. Effect of oral vitamin E (alphatocopherol) supplementation on vascular endothelial function in Type 2 diabetes mellitus. Diabet Med. 1999;16:304-311.
61. Nakagawa T, Sato W, Glushakova O, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol. 2007;18:539-550.
62. Zhang H, Zhang J, Ungvari Z, et al. Resveratrol improves endothelial function: role of TNF{alpha} and vascular oxidative stress. Arterioscler Thromb Vasc Biol. 2009;29:1164-1171.
63. Zhong JC, Yu XY, Huang Y, et al. Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res. 2007;74:388-395.
64. Zhong JC, Huang Y, Yung LM, et al. The novel peptide apelin regulates intrarenal artery tone in diabetic mice. Regul Pept. 2007;144:109-114.
65. Su J, Lucchesi PA, Gonzalez-Villalobos RA, et al. Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice. Arterioscler Thromb Vasc Biol. 2008;28: 1432-1438.
66. Wang Y, Huang Y, Lam KS, et al. Berberine prevents hyperglycemiainduced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. Cardiovasc Res. 2009;82:484-492.
67. Puddu P, Puddu GM, Cravero E, et al. The emerging role of cardiovascular risk factor-induced mitochondrial dysfunction in atherogenesis. J Biomed Sci. 2009;16:112.
68. Xu S, Ying J, Jiang B, Guo W, et al. Detection of sequence-specific tyrosine nitration of manganese SOD and SERCA in cardiovascular disease and aging. Am J Physiol Heart Circ Physiol. 2006;290:H2220-H2227.
69. Christensen FH, Stankevicius E, Hansen T, et al. Flow- and acetylcholine-induced dilatation in small arteries from rats with renovascular hypertension-effect of tempol treatment. Eur J Pharmacol. 2007;566:160-166.
70. Dal-Ros S, Oswald-Mammosser M, Pestrikova T, et al. Losartan prevents portal hypertension-induced, redox-mediated endothelial dysfunction in the mesenteric artery in rats. Gastroenterology. (In press).
71. Matsumoto T, Miyamori K, Kobayashi T, et al. Apocynin normalizes hyperreactivity to phenylephrine in mesenteric arteries from cholesterolfed mice by improving endothelium-derived hyperpolarizing factor response. Free Radic Biol Med. 2006;41:1289-1303.
72. Shi Y, So KF, Man RY, et al. Oxygen-derived free radicals mediate endothelium-dependent contractions in femoral arteries of rats with streptozotocin-induced diabetes. Br J Pharmacol. 2007;152:1033-1041. (Pubitemid 350166044)
73. Tesfamariam B, Jakubowski JA, Cohen RA. Contraction of diabetic rabbit aorta caused by endothelium-derived PGH2-TxA2. Am J Physiol. 1989;257:H1327-H1333.
74. Tesfamariam B, Brown ML, Deykin D, et al. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest. 1990;85:929-932.
75. Tesfamariam B, Cohen RA. Role of superoxide anion and endothelium in vasoconstrictor action of prostaglandin endoperoxide. Am J Physiol. 1992;262:H1915-H1919.
76. Tesfamariam B. Diabetes and vascular disease: functional alterations in adrenergic neurotransmission and endothelium. Curr Opin Nephrol Hypertens. 1995;4:92-97.
77. Shi Y, Feletou M, Ku DD, et al. The calcium ionophore A23187 induces endothelium-dependent contractions in femoral arteries from rats with streptozotocin-induced diabetes. Br J Pharmacol. 2007;150:624-632. (Pubitemid 46355551)
78. Shi Y, Vanhoutte PM. Oxidative stress and COX cause hyperresponsiveness in vascular smooth muscle of the femoral artery from diabetic rats. Br J Pharmacol. 2008;154:639-651.
79. Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114:597-605.
80. Gohda T, Tanimoto M, Moon JY, et al. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract. 2008;81:196-201.
81. Koyama H, Shoji T, Yokoyama H, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25: 2587-2593.
82. Harja E, Bu DX, Hudson BI, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE2/2 mice. J Clin Invest. 2008;118:183-194.
83. Forbes JM, Yee LT, Thallas V, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes. 2004;53:1813-1823.
84. Soro-Paavonen A, Watson AM, Li J, et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes. 2008;57:2461-2469.
85. Tsuruta R, Fujita M, Ono T, et al. Hyperglycemia enhances excessive superoxide anion radical generation, oxidative stress, early inflammation, and endothelial injury in forebrain ischemia/reperfusion rats. Brain Res. 2010;1309:155-163.
86. Sibal L, Agarwal SC, Schwedhelm E, et al. A study of endothelial function and circulating asymmetric dimethylarginine levels in people with type 1 diabetes without macrovascular disease or microalbuminuria. Cardiovasc Diabetol. 2009;8:27.
87. Benndorf RA, Appel D, Maas R, et al. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol. 2007;50:367-371.
88. Widlansky ME, Price DT, Gokce N, et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension. 2003;42:310-315.
89. Xiong W, Mactaggart J, Knispel R, et al. Inhibition of reactive oxygen species attenuates aneurysm formation in a murine model. Atherosclerosis. 2009;202:128-134.
90. Chan YC, Leung FP, Yao X, et al. Raloxifene modulates pulmonary vascular reactivity in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2007;49:355-361.
91. Luscher TF, Aarhus LL, Vanhoutte PM. Indomethacin improves the impaired endothelium-dependent relaxations in small mesenteric arteries of the spontaneously hypertensive rat. Am J Hypertens. 1990;3:55-58.
92. Hermann M, Camici G, Fratton A, et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation. 2003;108:2308-2311.
93. Jimenez R, Lopez-Sepulveda R, Kadmiri M, et al. Polyphenols restore endothelial function in DOCA-salt hypertension: role of endothelin-1 and NADPH oxidase. Free Radic Biol Med. 2007;43:462-473.
94. Garcia-Saura MF, Galisteo M, Villar IC, et al. Effects of chronic quercetin treatment in experimental renovascular hypertension. Mol Cell Biochem. 2005;270:147-155.
95. Heitzer T, Wenzel U, Hink U, et al. Increased NAD(P)H oxidasemediated superoxide production in renovascular hypertension: evidence for an involvement of protein kinase C. Kidney Int. 1999;55:252-260.
96. Quaschning T, Hocher B, Ruhl S, et al. Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension. Kidney Blood Press Res. 2006;29:351-359.
97. Huang PL, Huang Z, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.
98. Luscher TF, Raij L, Vanhoutte PM. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension. 1987;9:157-163.
99. Nunes VW, Fortes ZB, Nigro D, et al. Influence of enalapril on the endothelial function of DOCA-salt hypertensive rats. Gen Pharmacol. 2000;34:117-125.
100. Intengan HD, Schiffrin EL. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. Hypertension. 2000;35:1221-1225.
101. Lee J, Choi KC, Yeum CH, et al. Impairment of endothelium-dependent vasorelaxation in chronic two-kidney, one clip hypertensive rats. Nephrol Dial Transplant. 1995;10:619-623.
102. Shah DI, Singh M. Effect of demethylasterriquinone b1 in hypertension associated vascular endothelial dysfunction. Int J Cardiol. 2007;120: 317-324.
103. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension. 2004;44:186-190.
104. Higashi Y, Chayama K, YoshizumiM. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress. Curr Med Chem Cardiovasc Hematol Agents. 2005;3:133-148.
105. Higashi Y, Oshima T, Sasaki S, et al. Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculature to L-arginine in patients with essential hypertension. Hypertension. 1998;32:16-24.
106. Perrone-Filardi P, Corrado L, Brevetti G, et al. Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease. J Clin Hypertens (Greenwich). 2009;11:260-265.
107. Vanhoutte PM. Endothelium and control of vascular function. State of the art lecture. Hypertension. 1989;13:658-667.
108. Taddei S, Virdis A, Ghiadoni L, et al. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension. 1997;29: 274-279.
109. Campia U, Choucair WK, Bryant MB, et al. Role of cyclooxygenase products in the regulation of vascular tone and in the endothelial vasodilator function of normal, hypertensive, and hypercholesterolemic humans. Am J Cardiol. 2002;89:286-290.
110. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107:405-409.
111. Tang EH, Leung FP, Huang Y, et al. Calcium and reactive oxygen species increase in endothelial cells in response to releasers of endotheliumderived contracting factor. Br J Pharmacol. 2007;151:15-23.
112. Levy JV. Prostacyclin-induced contraction of isolated aortic strips from normal and spontaneously hypertensive rats (SHR). Prostaglandins. 1980;19:517-525.
113. Ge T, Hughes H, Junquero DC, et al. Endothelium-dependent contractions are associated with both augmented expression of prostaglandin H synthase-1 and hypersensitivity to prostaglandin H2 in the SHR aorta. Circ Res. 1995;76:1003-1010.
114. Rapoport RM, Williams SP. Role of prostaglandins in acetylcholineinduced contraction of aorta from spontaneously hypertensive and Wistar-Kyoto rats. Hypertension. 1996;28:64-75.
115. Gluais P, Lonchampt M, Morrow JD, et al. Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. Br J Pharmacol. 2005;146:834-845.
116. Tang EH, Jensen BL, Skott O, et al. The role of prostaglandin E and thromboxane-prostanoid receptors in the response to prostaglandin E2 in the aorta of Wistar Kyoto rats and spontaneously hypertensive rats. Cardiovasc Res. 2008;78:130-138.
117. Wong SL, Leung FP, Lau CW, et al. Cyclooxygenase-2-derived prostaglandin F2alpha mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ Res. 2009;104:228-235.
118. Leclercq B, Jaimes EA, Raij L. Nitric oxide synthase and hypertension. Curr Opin Nephrol Hypertens. 2002;11:185-189.
119. Sowers JR. Hypertension, angiotensin II, and oxidative stress. N Engl J Med. 2002;346:1999-2001.
120. Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 2000;101:235-238.
121. Arcaro G, Zenere BM, Saggiani F, et al. ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria. Diabetes Care. 1999;22:1536-1542.
122. Bijlstra PJ, Smits P, Lutterman JA, et al. Effect of long-term angiotensinconverting enzyme inhibition on endothelial function in patients with the insulin-resistance syndrome. J Cardiovasc Pharmacol. 1995;25:658-664.
123. O'Driscoll G, Green D, Rankin J, et al. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulindependent diabetes mellitus. J Clin Invest. 1997;100:678-684.
124. O'Driscoll G, Green D, Maiorana A, et al. Improvement in endothelial function by angiotensin-converting enzyme inhibition in noninsulin- dependent diabetes mellitus. J Am Coll Cardiol. 1999;33: 1506-1511.
125. Cheetham C, Collis J, O'Driscoll G, et al. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulindependent diabetes. J Am Coll Cardiol. 2000;36:1461-1466.
126. Cheetham C, O'Driscoll G, Stanton K, et al. Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. Clin Sci (Lond). 2001;100:13-17.
127. Braga MF, Leiter LA. Role of renin-angiotensin system blockade in patients with diabetes mellitus. Am J Cardiol. 2009;104: 835-839.
128. Hasegawa G, Fukui M, Hosoda H, et al. Telmisartan, an angiotensin II type 1 receptor blocker, prevents the development of diabetes in male Spontaneously Diabetic Torii rats. Eur J Pharmacol. 2009;605: 164-169.
129. Hsueh WA, Anderson PW. Systemic hypertension and the reninangiotensin system in diabetic vascular complications. Am J Cardiol. 1993;72:H14-H21.
130. Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int Suppl. 2000;75:S7-S14.
131. Raij L. Workshop: hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension. 2001;37:767-773.
132. Garcia G, Rodriguez-Puyol M, Alajarin R, et al. Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage. J Med Chem. 2009;52:7220-7227.
133. Kohli R, Meininger CJ, Haynes TE, et al. Dietary L-arginine supplementation enhances endothelial nitric oxide synthesis in streptozotocin- induced diabetic rats. J Nutr. 2004;134:600-608.
134. Pieper GM. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol. 1997;29:8-15.
135. Marletta MA, Yoon PS, Iyengar R, et al. Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry. 1988;27:8706-8711.
136. Lekakis JP, Papathanassiou S, Papaioannou TG, et al. Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol. 2002;86:317-323.
137. Regensteiner JG, Popylisen S, Bauer TA, et al. Oral L-arginine and vitamins E and C improve endothelial function in women with type 2 diabetes. Vasc Med. 2003;8:169-175.